Beverly Johns

No ORCID on file · 6 papers in corpus · active 2019-2021

Study types

  • article 5
  • other 1

Condition tags

  • endometriosis 6
  • mesh:D004715 2
  • dysmenorrhea 1
  • dyspareunia 1
article 2021
·doi:10.1016/j.fertnstert.2021.07.553
other 2020
Obstetrics and gynecology ·doi:10.1097/AOG.0000000000003917

OBJECTIVE: To evaluate the effects of elagolix on clinically meaningful improvements in health-related quality of life (HRQOL) measured by the EHP-30 (Endometriosis Health Profile-30). METHODS: Data from two phase III trials of elagolix fo…

article 2020
Journal of comparative effectiveness research ·doi:10.2217/cer-2020-0181

Aim: To evaluate impact of co-morbidities on opioid use in endometriosis. Patients & m ethods: This was a retrospective analysis of data obtained from the Symphony Health database (July 2015–June 2018), which contains medical and pharmacy c…

article 2020
ClinicoEconomics and outcomes research : CEOR ·doi:10.2147/ceor.s264905

PURPOSE: Elagolix is an oral gonadotropin-releasing hormone antagonist approved in the United States for the management of moderate to severe pain associated with endometriosis. We performed a real-world evaluation of the demographic and cl…

article 2020
·doi:10.1016/j.jval.2020.04.245
article 2019
·doi:10.1097/01.aog.0000558833.18140.6b

INTRODUCTION: Endometriosis is a chronic gynecologic disorder associated with several pain symptoms. This research evaluated opioids utilization following endometriosis diagnosis. METHODS: Women aged 18 to 49 who had one inpatient or 2 outp…